Get the Stockscreener App
16.80
5.69%
0.905
After Hours:
16.90
0.095
+0.57%
Tonix Pharmaceuticals Holding Corp stock is traded at $16.80, with a volume of 1.65M.
It is up +5.69% in the last 24 hours and down -9.75% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$15.90
Open:
$18.1
24h Volume:
1.65M
Relative Volume:
1.43
Market Cap:
$187.25M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-1.4925
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-0.21%
1M Performance:
-9.75%
6M Performance:
-39.98%
1Y Performance:
+28.18%
1-Day Range:
$16.27
$18.30
1-Week Range:
$15.50
$18.34
52-Week Range:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
16.80 | 187.25M | 0 | -121.02M | -114.09M | -11.26 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix set for best day in over two months as new fibromyalgia drug hits U.S. market - TradingView
Tonix Pharmaceuticals stock rises as TONMYA becomes available for fibromyalgia - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Launches Fibromyalgia Treatment TON - GuruFocus
Tonix Pharma Launches TONMYA Tablets in U.S. - TipRanks
Tonix’s first FDA-approved fibromyalgia drug in 15 years now available - Investing.com India
Tonix Pharmaceuticals teams up with MGH to advance Phase 2 trial of TNX-1500 - Proactive financial news
Tonix Pharmaceuticals Announces U.S. Availability of TONMYA for Fibromyalgia - TradingView
Tonix Pharma (Nasdaq: TNXP) Makes TONMYA Non-Opioid Fibromyalgia Drug Available - Stock Titan
Risk vs reward if holding onto Tonix Pharmaceuticals Holding Corp.July 2025 Review & Free Technical Pattern Based Buy Signals - newser.com
Will Tonix Pharmaceuticals Holding Corp. stock deliver shareholder valueJuly 2025 Big Picture & Technical Pattern Recognition Alerts - newser.com
How Tonix Pharmaceuticals Holding Corp. stock responds to policy changesGap Up & Safe Entry Trade Signal Reports - newser.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Raised to "Hold" at Wall Street Zen - MarketBeat
Volatility clustering patterns for Tonix Pharmaceuticals Holding Corp.2025 Price Action Summary & Weekly Consistent Profit Watchlists - newser.com
Will Tonix Pharmaceuticals Holding Corp. stock deliver strong dividend growthJuly 2025 Levels & Weekly Momentum Stock Picks - newser.com
Tonix Pharmaceuticals Holding Corp. stock trend forecastPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - newser.com
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook (NASDAQ:TNXP) - Seeking Alpha
Why (TNXP) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News - Yahoo Finance
Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results - MarketBeat
Tonix Readies First New Fibromyalgia Drug In 15 Years - Finimize
Can Tonix Pharmaceuticals Holding Corp. stock deliver strong Q4 earningsQuarterly Profit Report & AI Optimized Trade Strategies - newser.com
Real time alert setup for Tonix Pharmaceuticals Holding Corp. performancePortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Tonix Pharmaceuticals (TNXP) Q3 Revenue Surpasses Expectations - GuruFocus
Tonix Pharmaceuticals Reports Q3 2025 Earnings and Strategic Developments - TipRanks
Tonix Pharmaceuticals (TNXP) Q3 Earnings: Revenue Beats, EPS Mis - GuruFocus
Tonix Pharma earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Tonix Pharma earnings matched, revenue topped estimates - Investing.com
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights - The Manila Times
Tonix Pharmaceuticals Q3 net loss widens - MarketScreener
Tonix Pharmaceuticals Set to Launch Tonmya™ for Fibromyalgia Treatment, First New FDA-Approved Medicine in Over 15 Years - Quiver Quantitative
Is Tonix Pharmaceuticals Holding Corp. stock a safe haven assetMarket Trend Summary & High Accuracy Investment Signals - newser.com
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference - The Manila Times
How to build a dashboard for Tonix Pharmaceuticals Holding Corp. stockIndex Update & Low Drawdown Trading Techniques - newser.com
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.99%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):